Supriya Lifescience rose 1.52% to Rs 300.85 after the company said it received Certification of Suitability for anti-histamine therapy from the European Directorate for the Quality of Medicines and HealthCare.
The European Directorate for the Quality of Medicines and HealthCare (EDQM) has granted Certification of Suitability (CEP) to Supriya Lifescience for Diphenhydramine Hydrochloride, an API in anti-histamine therapy.This will be an added advantage for Supriya Lifescience in the European market. Global demand for Diphenhydramine Hydrochloride is 1850 tons, of which major demand is in the regulated markets, the company said in a statement.
Diphenhydramine is an antihistamine used to relieve symptoms of allergy, hay fever, and the common cold.
Supriya Lifescience has a presence in API ,anufacturing with focus in products of various therapeutic segments like - anti-histamine, anti-allergics, vitamins, anaesthetics, anti- asthmatics etc.
Net profit of Supriya Lifescience rose 226.23% to Rs 25.25 crore on 31.74% rise in net sales to Rs 101.36 crore in Q1 June 2022 over Q1 June 2021.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app